What Dulera Inhaler Treats: Main Uses and Benefits

The medication is commonly used to help with the long-term management of chronic breathing conditions in patients aged 5 years and older. It is relevant in therapeutic areas that involve supportive assistance from a combination of therapies, particularly when a patient's asthma is not adequately managed by a single controller medicine. The medication is applied in situations involving certain distressing symptoms across conditions like asthma, where combination treatment is appropriate. It is commonly used when patients experience conditions where symptoms may intensify temporarily or when their asthma is not adequately managed by a single controller.

It helps address symptom clusters that create noticeable physiological strain, including persistent wheezing, recurrent shortness of breath, and situations involving chest tightness. The combination therapy generally supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.

“The therapeutic support may assist in the management of chronic airway symptoms, contributing to improved day-to-day comfort as part of a long-term plan.”

---

Quick Fact: Relief for Chronic Respiratory Symptoms
Primary Therapeutic Goal	Long-term symptomatic control of chronic asthma
Key Symptom Clusters	Wheezing, shortness of breath, and chest tightness
Typical Context of Use	Applied for long-term symptom management, rather than for addressing acute, sudden breathing problems
Patient Benefit	Contributes to maintaining functional stability and supports general well-being during symptomatic phases

Regulatory References

1. DailyMed Label for Dulera

Official Eligibility and Contraindications

Classification	Regulatory Status
Approved Age Group	Patients 5 years of age and older are approved for use [Source 2.6]. Safety and efficacy are not established in children younger than 5 years of age [Source 2.3].
Use Condition	Approved only for patients whose asthma is not adequately controlled on an inhaled corticosteroid alone, or whose disease severity warrants a combination therapy [Source 1.7].
Contraindicated Populations	Prohibited in patients with a known hypersensitivity to any component of the inhaler [Source 1.6].
Acute Status Restriction	Contraindicated for the primary treatment of status asthmaticus or for the relief of acute bronchospasm [Source 1.1].

Populations Requiring Caution

Use of this medicine requires caution and monitoring in patients with certain coexisting conditions, as defined in the official regulatory label:

• Cardiovascular Conditions: Patients with heart disorders, high blood pressure, or a history of aneurysm [Source 1.3].
• Metabolic/Systemic Conditions: Patients with diabetes mellitus, thyrotoxicosis, or specific infections such as active or quiescent tuberculosis [Source 1.4].
• Reproductive Status: Data are inadequate regarding risk during pregnancy; caution is advised during lactation as it is unknown if the components are excreted in human milk [Source 1.1].

Dulera Inhaler is a combination product containing formoterol, a long-acting beta2-agonist (LABA), and mometasone furoate, an inhaled corticosteroid. The potential for interaction with other medicines stems from the properties of both components.

Potential Drug-Drug Interactions

Interacting Product Category	Potential Effect	Caution Level
Other Long-Acting Beta2-Agonists (LABAs)	Risk of overdose and serious adverse effects (e.g., chest pain, increased heart rate).	Contraindicated (Do Not Use)
Strong CYP3A4 Inhibitors (e.g., ritonavir, ketoconazole, cobicistat-containing products)	May increase the systemic exposure to the mometasone component, potentially leading to Cushing's syndrome or adrenal suppression.	Use with caution; monitoring recommended.
MAO Inhibitors, Tricyclic Antidepressants, Macrolides, and QTc-Prolonging Drugs	May potentiate the formoterol component's effect on the cardiovascular system, increasing the risk of ventricular arrhythmias.	Use with extreme caution.
Beta-Blockers (e.g., propranolol)	May block the bronchodilating effect of formoterol and cause severe bronchospasm. Cardioselective beta-blockers should be considered if necessary.	Use with caution, only when medically necessary.
Non-Potassium-Sparing Diuretics (e.g., thiazide, loop diuretics) & Xanthine Derivatives	May worsen the hypokalemia and/or ECG changes that can be caused by formoterol.	Use with caution.
Adrenergic Agents (additional)	May potentiate the sympathetic effects of formoterol.	Use with caution.
Halogenated Hydrocarbon Anesthetics	Elevated risk of arrhythmias if used during concomitant anesthesia.	Use with caution.

Patients should inform their healthcare provider of all prescription and over-the-counter medicines, vitamins, and herbal supplements currently being taken to properly assess the risk of interaction.

Regulating Chronic Airway Inflammation

This domain involves Mometasone Furoate acting as an agonist on the intracellular Glucocorticoid Receptor (GR). This interaction modulates gene expression, initiating a cascade that suppresses the synthesis of pro-inflammatory mediators like cytokines and chemokines, leading to a long-term reduction in tissue swelling and the hyper-responsiveness of the airways. This mechanism modulates physiological responses driven by excessive inflammatory pathway activation.

---

Sustained Bronchial Muscle Relaxation

Formoterol Fumarate targets the Beta-2 Adrenergic Receptors (beta2-AR) on the airway smooth muscle. Its partial agonism rapidly activates the adenylyl cyclase/cAMP cascade, which ultimately halts the contraction mechanism by inactivating Myosin Light Chain Kinase (MLCK). This continuous molecular interference with the smooth muscle's contractile state results in continuous muscle relaxation and sustained widening of the bronchial passages.

---

Inter-Component Mechanistic Synergy

Mometasone helps to counteract the functional down-regulation of the beta2-AR targets by upregulating their expression, thereby mitigating the functional down-regulation of the Formoterol beta2-AR target over time. This synergistic domain contributes to the functional modulation of the overall beta2-AR physiological response. This combined action results in the modulation of both the reactivity and the tone of the bronchial passages.

How to Use Dulera Inhaler

Dulera is a long-term maintenance treatment administered exclusively via the Oral Inhalation route using a Pressurized Metered-Dose Inhaler (pMDI). Its usage is defined by a fixed, routine twice-daily schedule, with doses intended for morning and evening administration. It is essential that this product is used every day for maintenance and is not intended for the immediate relief of acute breathing problems.

Standard Dosing and Frequency

The standard regimen across all approved strengths is two inhalations twice daily. This medication is available in three strengths of Mometasone/Formoterol: 50 mcg/5 mcg, 100 mcg/5 mcg, and 200 mcg/5 mcg. The total maximum recommended daily dosage is two inhalations of the 200 mcg/5 mcg strength taken twice daily. If a dose is missed, patients should take the next scheduled dose at the usual time and not take extra inhalations to compensate.

Population-Specific Use

Usage rules vary by age group. Adults and adolescents (ge 12 years) are typically prescribed the 100 mcg/5 mcg or 200 mcg/5 mcg strength. Pediatric patients (5 to <12 years) are limited to the 50 mcg/5 mcg strength, taking two inhalations twice daily.

Essential Administration Instructions

Proper use involves specific procedural steps. The inhaler must be shaken well before each use. A new inhaler requires priming with 4 test sprays prior to initial use, and re-priming is required if unused for 5 or more days. A critical instruction after each twice-daily dose is to rinse the mouth with water and spit out the contents without swallowing.

Research Evidence / Overview of Studies for Dulera Inhaler

This overview summarizes the types of clinical studies conducted for the Mometasone Furoate and Formoterol Fumarate Dihydrate combination, detailing what researchers explored and what remains to be fully established, as described in scientific literature.

1. Evidence for Use in Persistent Asthma

The core evidence comes primarily from Randomized Controlled Trials (RCTs) conducted over 12 to 26 weeks. These studies contributed to the regulatory review of the medicine for the long-term management of persistent asthma. Research explored key functional and symptomatic outcomes, including objective measurements of lung function, such as the Forced Expiratory Volume in 1 second ( FEV1), and patient-reported experiences using validated questionnaires. The trials were structured to examine whether measured changes in lung function with the combination product differed from those observed with its individual components alone. While research provides insight into short-term changes, certain long-term effects and the durability of response are not consistently characterized.

2. Research on Long-Term Safety and Study Duration

Because of regulatory concerns regarding the Long-Acting Beta-Adrenergic Agonist ( LABA) component, large-scale Post-Marketing Safety Trials were mandated. These were not designed to test core functional outcomes, but rather to look closely at the rate of Serious Asthma Outcomes (SAOs), which include asthma-related hospitalization. While core efficacy studies ran for up to 26 weeks, these dedicated safety studies monitored patient outcomes over longer periods, with observation extending up to 52 weeks. This highlights the use of short-term, controlled studies for initial functional measurements and longer-term, large studies dedicated specifically to monitoring safety.

3. Evidence in Specific Age Groups and Research Gaps

The majority of core evidence was derived from studies involving adults and adolescents (ge 12 years). Separate research examined children between 5 and 11 years of age, focusing primarily on pharmacokinetic and safety profiles. However, data for certain groups remain insufficient, and research is ongoing. Long-term effects are not fully established beyond the one-year follow-up, and limited information is available for outcomes related to continuous functional stability over the long term. Comparative evidence is lacking against every other available treatment option, as studies often focused on comparing the product against its own components or placebo.

Key Studies & References

1. A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) [ClinicalTrials.gov Identifier: NCT01471340]
2. Mometasone furoate/formoterol in the treatment of persistent asthma (Review detailing RCT findings on FEV1 and duration)
3. Merck Announces Top-Line Results from the Long Term LABA Safety Study of DULERA (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol

Common questions about Dulera Inhaler (FAQ)

Q: How is the Dulera Inhaler different from a short-acting inhaler like albuterol?

A: The official product information clarifies that Dulera Inhaler is a controller medicine intended for long-term daily maintenance of chronic asthma. It contains both an inhaled steroid and a long-acting bronchodilator (LABA).

This makes its role distinct from a short-acting rescue inhaler, such as albuterol, which is used only for the immediate relief of sudden breathing issues and not for daily, sustained control.

Q: Can the Dulera Inhaler cause feelings of anxiety or nervousness?

A: Regulatory documents state that potential side effects associated with the long-acting bronchodilator component include nervousness and tremor. These effects can sometimes be symptoms of using more than the prescribed amount of the medicine.

Official information suggests consulting a healthcare provider if these effects are concerning.

Q: Can people with a history of heart problems or high blood pressure use the Dulera Inhaler?

A: Official product information advises that the medicine should be used with caution in patients who have a history of certain cardiovascular conditions, including heart disease or high blood pressure.

Reporting a history of these conditions to a healthcare provider is consistent with official guidance for monitoring, as the bronchodilator component may affect the heart and circulatory system.

Q: Can Dulera Inhaler interact with medicines used for depression or other mental health conditions?

A: Regulatory documents advise extreme caution when Dulera Inhaler is used alongside certain medicines for depression, specifically MAO inhibitors and tricyclic antidepressants.

This is because combining these medications may increase the risk of serious effects on the heart and circulatory system. Official documentation recommends reporting a complete list of all medicines to a healthcare provider.

Q: Is it safe to stop using the Dulera Inhaler suddenly on my own?

A: Abruptly stopping the medicine, especially after long-term use, may be unsafe. The inhaled steroid component carries a risk of effects like adrenal suppression (reduced adrenal gland function), which can be worsened if the medicine is discontinued suddenly.

It is recommended in the official documentation that patients consult a healthcare provider before changing their dosing schedule.

Q: Is weight gain a known side effect of the Dulera Inhaler?

A: While weight gain is not listed among the most common side effects, it may be a symptom of a serious systemic effect from the inhaled steroid component, such as Cushing syndrome.

This risk is linked to the body potentially absorbing too much of the steroid. The official label recommends discussing any unexpected changes in weight with a healthcare provider.

Q: Can Dulera Inhaler affect blood sugar or potassium levels?

A: Official warnings state that the medicine can lead to a decrease in blood potassium levels (hypokalemia) and an increase in blood sugar levels (hyperglycemia).

For this reason, caution and monitoring may be necessary for patients with pre-existing conditions like diabetes.

Q: Can a person use this inhaler if they have a history of seizures?

A: The medicine should be used with caution in individuals with convulsive disorders (seizures). Furthermore, the official prescribing information notes that seizures are a potential serious effect associated with using more than the prescribed amount of the medicine.

Official information notes that patients should inform their healthcare provider of any history of seizures.

Q: Are there any cold, flu, or antibiotic medications that interact with Dulera Inhaler?

A: Yes, regulatory documents identify certain medications that can interact, including the antibiotic clarithromycin and other strong CYP3A4 inhibitors. These medicines can slow the breakdown of the mometasone component in the body.

This may increase the amount of the medicine circulating in the body, which raises the risk of steroid-related side effects.

Q: Can certain foods or supplements interact with the Dulera Inhaler?

A: Official documents generally recommend that patients inform their healthcare provider about all vitamins, herbal supplements, and other over-the-counter products being taken.

The product information also notes that there is a risk of interactions with alcohol and certain foods that may affect how the drug is metabolized.

Q: What are the risks if I accidentally use more puffs of Dulera Inhaler than prescribed?

A: Using more than the prescribed number of puffs can lead to signs of overdose due to the long-acting bronchodilator component. Regulatory information lists serious effects such as chest pain, fast or irregular heartbeat, headache, and tremor.

The official label warns that patients experiencing these effects should seek emergency medical attention.

Q: Does Dulera Inhaler have a generic version available yet?

A: According to the regulatory review and approval records in the United States, a generic version of the Dulera Inhaler is not currently approved or available on the market.

Only the brand-name product has been approved for use.

Q: Can the Dulera Inhaler cause a change in voice or hoarseness?

A: Yes, regulatory safety information states that hoarseness or a deepened voice (dysphonia) has been reported by a small number of patients in clinical studies.

This is a known, though not highly common, adverse reaction associated with using the inhaler.

Q: How long does it take for the effects of Dulera Inhaler to start working?

A: Dulera is a controller medication that is taken daily for long-term support, and its effects are not immediate.

Official prescribing information states that the medicine's full maximum benefit for asthma management may not be reached until one week or longer after starting daily treatment.

Q: How long does the effect of one dose of Dulera Inhaler typically last?

A: The medicine is designed to provide sustained control over chronic airway issues for a fixed period.

Because it contains a long-acting bronchodilator, the dosing schedule is set for twice daily (morning and evening) to maintain consistent support over a 12-hour interval.

Q: Is it known if the ingredients in Dulera Inhaler pass into breast milk?

A: According to the FDA Medication Guide, it is not known if the active ingredients in Dulera Inhaler pass into human breast milk. Consequently, it is also not known if the medicine could cause harm to a nursing infant.

Official sources state that patients should consult their healthcare provider for specific guidance regarding use during lactation.

How to Store and Dispose of Dulera Inhaler

Storage of the Dulera inhaler must comply with strict temperature and pressure requirements. The inhaler must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C (86 F).

Canister and Protection Rules

• Heat Restriction: The contents are under pressure; the canister must not be punctured, or exposed to temperatures above 49 C (120 F), which can cause it to burst. Do not store or use near heat or open flame.
• Position: The 60-puff inhaler should be stored with the mouthpiece down or sideways after priming.
• Child Safety: Keep the product strictly out of the reach of children.

Disposal Requirements

The inhaler must be discarded when the dose counter reads zero (0). For final disposal, do not throw the container into a fire or incinerator. Unused product and empty canisters should be disposed of in accordance with local regulations for pressurized canisters.